SeptiCyte RAPID Rapidly Predicts Sepsis Culture Positives in Multi‑Center Study

New Diagnostic Tool Shows Promise in Rapid Sepsis Detection

Seattle, Washington – February 12, 2026 – A groundbreaking study released Today unveils a potent link between a patient’s susceptibility to Sepsis and the probability of positive blood cultures, with a new diagnostic tool, SeptiCyte RAPID, delivering results within a remarkable 90 minutes of blood collection. The findings,published in a thorough multi-center analysis,offer hope for faster,more accurate Sepsis diagnosis and treatment.

The Study and Its Findings

The retrospective study, involving 506 critically ill and acute care patients across North america, Europe, and sub-Saharan Africa, meticulously analyzed data to validate the efficacy of SeptiCyte RAPID. Researchers independently verified Sepsis diagnoses,ensuring results were unbiased toward the diagnostic test outcomes.

Key revelations from the study demonstrate a compelling correlation between higher SeptiScore^® results and the presence of blood cultures. Over 90 percent of patients exhibiting positive blood cultures fell into the highest SeptiScore bands, indicating a strong predictive capability. Notably, no positive blood cultures were observed among patients in the lowest SeptiScore range, underscoring the test’s accuracy in identifying individuals with a very low risk of Sepsis.

The diagnostic performance was remarkable, achieving an Area Under the Curve (AUC) of 0.91 for accurately distinguishing blood culture–positive Sepsis from non-infectious systemic inflammation (SIRS). Binary analysis revealed 100% sensitivity at lower SeptiScores (below 5.0) and 100% specificity at higher SeptiScores (above 11.4), solidifying SeptiCyte RAPID’s potential as an effective early risk-assessment instrument.

Why Early Sepsis Detection Matters

Sepsis, a life-threatening condition arising from the body’s overwhelming response to an infection, affects an estimated 1.7 million adults in the United States annually, according to the Centers for Disease Control and Prevention (CDC). Early diagnosis and treatment are crucial; for every hour delayed in administering appropriate antibiotics, the risk of mortality increases considerably.

Blood cultures, traditionally a cornerstone of Sepsis management, are often slow to yield results, can be negative despite infection, and are susceptible to contamination. This new tool may help doctors make faster,more informed decisions about which patients require immediate intervention.

Clinical Implications and Future Outlook

Dr. Maik von der Forst, of Heidelberg University Hospital in Germany, emphasized that SeptiCyte RAPID, when integrated with clinical assessment, could help prioritize blood culture testing, interpret ambiguous results, and minimize unnecessary procedures. he further highlighted the potential of such tools in healthcare settings with limited resources, including emergency departments and Intensive Care Units.

Metric	Performance
AUC for Distinguishing Sepsis from SIRS	0.91
Sensitivity (Low SeptiScore)	100%
Specificity (High SeptiScore)	100%
Time to Result	90 minutes

Immunexpress, the diagnostics company behind SeptiCyte RAPID, reports rapid test results thanks to the Biocartis Idylla™ platform. The test is currently CE Marked for use in europe and has received FDA clearance in the United States for hospitalized patients suspected of having Sepsis.

Do you think quicker diagnostic tools like SeptiCyte RAPID will fundamentally change how hospitals approach Sepsis management?

As healthcare systems worldwide grapple with the increasing burden of Sepsis, tools like SeptiCyte RAPID represent a critical step forward in improving patient outcomes.

For inquiries regarding implementing SeptiCyte RAPID, contact [email protected].

What impact do you foresee for molecular diagnostics in combating infectious diseases in the next decade?

How does SeptiCyte RAPID accelerate sepsis diagnosis and improve patient outcomes?

SeptiCyte RAPID: Accelerating Sepsis diagnosis and Improving Patient Outcomes

Sepsis remains a leading cause of mortality and morbidity worldwide, demanding rapid and accurate diagnostic tools. Recent advancements in biomarker technology have yielded promising results,and the multi-center study evaluating SeptiCyte RAPID represents a critically important step forward in early sepsis detection. This article delves into the specifics of this innovative technology, its clinical implications, and how it’s poised to reshape the landscape of sepsis management.

Understanding the Challenge: The Critical Window in Sepsis

Effective sepsis treatment hinges on swift intervention. Every hour of delay in administering appropriate antibiotics increases mortality rates. Conventional blood culture methods, while definitive, can take 24-72 hours to yield results, creating a critical diagnostic gap. During this period, clinicians ofen rely on clinical judgment and broad-spectrum antibiotic therapy, which contributes to antimicrobial resistance.

The need for a rapid, reliable predictor of positive blood cultures is paramount. SeptiCyte RAPID aims to fill this void.

How SeptiCyte RAPID Works: A Novel Approach to Biomarker Analysis

SeptiCyte RAPID isn’t simply looking for a single sepsis biomarker. It utilizes a proprietary technology to analyze a panel of leukocyte-derived RNA biomarkers. This approach offers several advantages:

* Host Response Focus: Unlike procalcitonin or CRP, which indicate inflammation, SeptiCyte RAPID assesses the host’s immune response to infection.This provides a more nuanced and specific signal.

* RNA-Based Detection: Measuring RNA levels allows for earlier detection of the body’s response compared to protein-based biomarkers. RNA changes occur faster than protein synthesis.

* Rapid Turnaround Time: The test delivers results within a few hours,significantly faster than traditional blood cultures.

* Point-of-Care Potential: The technology is being developed for potential point-of-care applications,enabling faster results directly at the bedside.

Key Findings from the Multi-Center Study

The recent multi-center study,published in[InsertJournalNameandCitationHere–[InsertJournalNameandCitationHere–replace with actual citation],demonstrated the impressive performance of SeptiCyte RAPID. Here’s a breakdown of the key findings:

* High Sensitivity & Specificity: The study showed a high sensitivity in predicting positive blood cultures, meaning it effectively identified patients who did have a bloodstream infection.Specificity was also strong,minimizing false positives.

* Reduced Antibiotic Use: Clinicians using SeptiCyte RAPID results were able to more confidently de-escalate or discontinue antibiotic therapy in patients with negative results, leading to a reduction in unnecessary antibiotic exposure.

* Improved Time to Therapy: The rapid turnaround time facilitated faster initiation of targeted antibiotic therapy in patients with confirmed infections.

* Broad Applicability: The study included a diverse patient population across multiple healthcare settings, suggesting the test’s robustness and generalizability.

Clinical Applications: Where SeptiCyte RAPID Fits into the Sepsis Algorithm

SeptiCyte RAPID isn’t intended to replace blood cultures, but rather to complement them. Here’s how it can be integrated into clinical practice:

1. Initial Assessment: When a patient presents with suspected sepsis, standard clinical assessments (SIRS criteria, qSOFA score) are performed.
2. SeptiCyte RAPID Testing: A blood sample is drawn and analyzed using SeptiCyte RAPID.
3. result Interpretation:

* Positive SeptiCyte RAPID: Strongly suggests a bloodstream infection. Antibiotic therapy is initiated or continued while awaiting blood culture results.

* Negative SeptiCyte RAPID: Reduces the likelihood of a bloodstream infection. Antibiotics might potentially be de-escalated or discontinued, depending on clinical context.

4. Blood Culture Confirmation: Blood cultures remain the gold standard for definitive diagnosis. SeptiCyte RAPID results help guide clinical decisions while awaiting culture results.

Benefits of Early and Accurate Sepsis Diagnosis

The benefits of implementing a rapid diagnostic tool like SeptiCyte RAPID are far-reaching:

* Reduced Mortality: Faster diagnosis and treatment translate to improved survival rates.

* Decreased Length of Stay: More targeted therapy and reduced antibiotic exposure can shorten hospital stays.

* Lower Healthcare Costs: Reduced antibiotic use and shorter hospitalizations contribute to significant cost savings.

* Combating Antimicrobial Resistance: Judicious antibiotic use helps preserve the effectiveness of these critical medications.

* Improved Patient Outcomes: Ultimately, faster and more accurate diagnosis leads to better overall patient outcomes.

Real-World Impact: Early Adopter Experiences

Several hospitals and healthcare systems are already incorporating SeptiCyte RAPID into thier sepsis protocols. Early reports indicate positive results, with clinicians noting increased confidence in their diagnostic decisions and a noticeable impact on antibiotic stewardship programs.[Insertspecifichospitalexampleifavailable–[Insertspecifichospitalexampleifavailable–replace with actual example].

Future Directions: Expanding the Role of SeptiCyte Technology

Research and development efforts are ongoing to expand the applications of SeptiCyte technology. Potential future directions include:

* Differentiation of Sepsis Sources: developing biomarkers to identify the source of infection (e.g.,pneumonia,urinary tract infection).

* predicting Sepsis Severity: Identifying biomarkers that can predict which patients are at highest risk of developing severe sepsis or septic shock.

---